arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Curanex Pharmaceuticals Inc

CURX
$4.46 ▼ -0.16 (-3.36%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
17 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Bearish
auto_awesome

Analytical Summary

Curanex Pharmaceuticals Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $113.7M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -29.8% ↗
FCF / Share $-0.41 ↘
Trailing P/E —
Price / Book 11.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-4.23M
↓ -1068.8% —
FCF / Share Free cash flow per share
$-0.41
↓ -881.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
20
Cash Quality ↑
89

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 3 years · 11 quarters